8EV.F EVGEN PHARMA PLC LS-0025

Healthcare Biotechnology Frankfurt Exchange
0.0025 EUR
Close of Nov 11, 2026
0.0005 0.0170
Market cap
EUR 5.29M
P/E
-
P/B
0.33x
ROE
-130.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is 8EV.F undervalued?

Graham number

The Graham number of EVGEN PHARMA PLC LS-0025 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EVGEN PHARMA PLC LS-0025 fundamental analysis

No fundamental analysis for EVGEN PHARMA PLC LS-0025 yet.

EVGEN PHARMA PLC LS-0025 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EVGEN PHARMA PLC LS-0025

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed it…

Full company profile